Mortality due to septic-shock-induced respiratory failure remains high. A recent meta-analysis suggested that IgM-enriched immunoglobulin treatment may be beneficial in these patients. In this prospective randomised controlled pilot study we investigated the effects of IgM-enriched immunoglobulin treatment in patients with early septic shock accompanied by severe respiratory failure. 33 patients were randomly allocated to receive 5 ml/kg (predicted body weight) IgM-enriched immunoglobulin (16 patients) or placebo (17 patients), respectively, via 8 h IV-infusion for three consecutive days. Daily Multiple Organ Dysfunction Scores (MODS) were calculated. Serum C-reactive protein (CRP) and procalcitonin (PCT) levels were monitored daily. For statistical analysis two-way ANOVA was used. Daily MODS showed ongoing multiple system organ failure without significant resolution during the 8 days. Median length of ICU stay, mechanical ventilation, vasopressor support during the ICU stay and 28-day mortality were nearly identical in the two groups. Serum PCT levels showed no significant difference between the two groups, however, CRP levels were significantly lower in the IgM-enriched immunoglobulin group on days 4, 5 and 6, respectively. In this study the use of IgM-enriched immunoglobulin preparation failed to produce any improvement in the organ dysfunction as compared to standard sepsis therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00540-012-1553-9DOI Listing

Publication Analysis

Top Keywords

igm-enriched immunoglobulin
24
effects igm-enriched
8
multiple organ
8
organ failure
8
pilot study
8
respiratory failure
8
immunoglobulin treatment
8
organ dysfunction
8
pct levels
8
icu stay
8

Similar Publications

: Infections frequently occur after orthotopic liver transplantation (OLT) and are associated with increased mortality. In 2018, we introduced perioperative administration of intravenous immunoglobulin enriched in IgM as an optional therapy in recipients at a high risk of infection. This preliminary study evaluated whether this preparation reduced infections in the early post-transplantation period.

View Article and Find Full Text PDF

Background And Aim: Coronavirus disease 2019 (COVID-19) led to a major global health crisis, leading to a worldwide pandemic. Several therapeutic interventions have been tried with varied results. The purpose of this academic work was to assess the efficacy of immunoglobulin M (IgM)-enriched Ig in the management of patients with severe COVID-19 pneumonia.

View Article and Find Full Text PDF

Background: Sepsis is an overwhelming reaction to infection that comes with high morbidity and mortality. It requires urgent interventions in order to improve outcomes. Intravenous immunoglobulins (IVIG) are considered as potential therapy in sepsis patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the potential benefits of IgM-enriched intravenous immunoglobulins (IGAM) for severe COVID-19 patients, focusing on those who are often admitted to intensive care during advanced stages when other treatments are less effective.
  • Conducted at a university hospital in Italy, the research compares outcomes of 56 patients treated with Pentaglobin IGAM to a control group of 169 untreated patients from March 2020 to April 2021.
  • Results indicate that IGAM-treated patients experienced shorter timeframes to hospitalization and better clinical markers (lower D-dimer and improved P/F ratio), suggesting that IGAM treatment may have protective effects against mortality.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!